Carole Ho
CIK: 0001724605
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 5, 2026RPRX
Royalty Pharma plc
Award(A)Direct4.5K shares- - Aug 13, 2025DNLI
Denali Therapeutics Inc.
Sale(S)Direct806 shares at avg. $14.64$12K - Aug 12, 2025DNLI
Denali Therapeutics Inc.
Sale(S)Direct2.9K shares at avg. $13.58$40K - Aug 5, 2025DNLI
Denali Therapeutics Inc.
Exercise(M)Direct44.7K shares at avg. $0.68$30K - Jul 31, 2025RPRX
Royalty Pharma plc
Award(A)Direct2.8K shares- - Jul 31, 2025RPRX
Royalty Pharma plc
Award(A)Direct5.8K shares- - Jun 4, 2025BEAM
Beam Therapeutics Inc.
Award(A)DirectStock Option (Right to Buy)
33.7K shares- - Jan 7, 2025DNLI
Denali Therapeutics Inc.
Sale(S)Direct2.9K shares at avg. $20.81$60K - Jan 6, 2025DNLI
Denali Therapeutics Inc.
Sale(S)Direct12.3K shares at avg. $20.22$248K - Jan 3, 2025DNLI
Denali Therapeutics Inc.
Award(A)Direct54.2K shares- - Nov 25, 2024DNLI
Denali Therapeutics Inc.
Exercise(M)Direct17.8K shares at avg. $0.68$12K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  RPRX Royalty Pharma plc | Award(A) | 4,545 | - | $0 | Direct |
| Aug 13, 2025 |  DNLI Denali Therapeutics Inc. | Sale(S) | 806 | $14.64 | $11,800 | Direct |
| Aug 12, 2025 | DNLI Denali Therapeutics Inc. | Sale(S) | 2,937 | $13.58 | $39,884 | Direct |
| Aug 5, 2025 | DNLI Denali Therapeutics Inc. | Exercise(M) | 44,655 | $0.68 | $30,365 | Direct |
| Jul 31, 2025 | RPRX Royalty Pharma plc | Award(A) | 2,752 | - | - | Direct |
| Jul 31, 2025 | RPRX Royalty Pharma plc | Award(A) | 5,806 | - | - | Direct |
| Jun 4, 2025 |  BEAM Beam Therapeutics Inc. | Award(A) Stock Option (Right to Buy) | 33,662 | - | - | Direct |
| Jan 7, 2025 | DNLI Denali Therapeutics Inc. | Sale(S) | 2,907 | $20.81 | $60,495 | Direct |
| Jan 6, 2025 | DNLI Denali Therapeutics Inc. | Sale(S) | 12,255 | $20.22 | $247,796 | Direct |
| Jan 3, 2025 | DNLI Denali Therapeutics Inc. | Award(A) | 54,180 | - | $0 | Direct |
| Nov 25, 2024 | DNLI Denali Therapeutics Inc. | Exercise(M) | 17,845 | $0.68 | $12,135 | Direct |
1-11 of 11 transactions
About Ho Carole
Ho Carole (SEC CIK 0001724605) files insider reports with the SEC as Director of Royalty Pharma plc (RPRX), EVP & Pres, Lilly Neuroscience of ELI LILLY & Co (LLY) and Chief Medical Officer of Denali Therapeutics Inc. (DNLI). Signal8 also holds filings tied to 1 other company.
Signal8 holds 10 ownership filings by Ho Carole (2 Form 3, 8 Form 4), filed between Nov 27, 2024 and Jun 8, 2026. Those filings report 11 transactions, from Nov 25, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Ho Carole's filings is in NEW YORK, NY.
Recent filings by Ho Carole
- Jun 5, 2026: Grant or award of RPRX shares (Form 4, code A).
- Aug 13, 2025: Open-market sale of DNLI shares (Form 4, code S).
- Aug 12, 2025: Open-market sale of DNLI shares (Form 4, code S).
- Aug 5, 2025: Option exercise of DNLI shares (Form 4, code M).
- Jul 31, 2025: Grants or awards of RPRX shares (2 lines, Form 4, code A).
Other insiders filing for Royalty Pharma plc (RPRX)
- Urist Marshall, EVP, Research & Investments
- Bassler Bonnie L, Director
- Hite Christopher, EVP & Chairman, Partnering
- Coyne Terrance P., EVP & CFO
- Legorreta Pablo G., CEO, Chairman of the Board
- WEATHERMAN ELIZABETH H, Director